Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Non Operating Income (2016 - 2025)

Regenxbio has reported Non Operating Income over the past 12 years, most recently at -$9.5 million for Q4 2025.

  • Quarterly results put Non Operating Income at -$9.5 million for Q4 2025, down 5326.92% from a year ago — trailing twelve months through Dec 2025 was -$32.7 million (down 623.38% YoY), and the annual figure for FY2025 was -$32.7 million, down 623.38%.
  • Non Operating Income for Q4 2025 was -$9.5 million at Regenxbio, roughly flat from -$9.5 million in the prior quarter.
  • Over the last five years, Non Operating Income for RGNX hit a ceiling of $3.1 million in Q3 2023 and a floor of -$9.5 million in Q3 2025.
  • Median Non Operating Income over the past 5 years was -$3.3 million (2022), compared with a mean of -$2.9 million.
  • Biggest five-year swings in Non Operating Income: surged 202.7% in 2024 and later tumbled 5326.92% in 2025.
  • Regenxbio's Non Operating Income stood at -$6.2 million in 2021, then soared by 64.23% to -$2.2 million in 2022, then surged by 139.06% to $862000.0 in 2023, then tumbled by 78.89% to $182000.0 in 2024, then tumbled by 5326.92% to -$9.5 million in 2025.
  • The last three reported values for Non Operating Income were -$9.5 million (Q4 2025), -$9.5 million (Q3 2025), and -$7.6 million (Q2 2025) per Business Quant data.